AMGN vs BMY: fair value comparison
Amgen Inc. and Bristol-Myers Squibb Company · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BMY currently sits closer to the top of our discount ranking. AMGN carries the stronger quality grade.
| AMGN | BMY | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $437.23 | $66.82 |
| 12-month range | $294.20–$438.12 | $46.02–$66.92 |
| Sector rank | #105 of 113 Healthcare | #100 of 113 Healthcare |
| Quality grade | B | C |
| Leverage | High | High |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · BMY fair value analysis